4
Changes in Ownership
Axsome Therapeutics, Inc. Filed Acc 0001193125-26-006695
Chief Executive Officer sold 139,414 shares at an average $171.30 ($23,881,618)
- Chief Executive Officer acquired 139,414 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
TABUTEAU HERRIOT · Chief Executive Officer
Table I: Non-derivative
6 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-01-05 | Exercise or conversion : show line 1 in the form 10b5-1 | +78,703 | $8.02 | $631,198 | 85,932 | D |
| 2026-01-05 | Sale : show line 2 in the form 10b5-1 | −78,703 | $171.28 | $13,480,250 | 7,229 | D |
| 2026-01-06 | Exercise or conversion : show line 3 in the form 10b5-1 | +29,450 | $8.02 | $236,189 | 36,679 | D |
| 2026-01-06 | Sale : show line 4 in the form 10b5-1 | −29,450 | $172.33 | $5,075,119 | 7,229 | D |
| 2026-01-07 | Exercise or conversion : show line 5 in the form 10b5-1 | +31,261 | $8.02 | $250,713 | 38,490 | D |
| 2026-01-07 | Sale : show line 6 in the form 10b5-1 | −31,261 | $170.38 | $5,326,249 | 7,229 | D |
| Open-market sales · 139,414 sh · avg $171.30 · $23,881,618 | ||||||
Table II: Derivative
3 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-01-05 | Exercise or conversion : show line 7 in the form 10b5-1 Stock Option (Right to Buy) | −78,703 | 93,121 | D |
| 2026-01-06 | Exercise or conversion : show line 8 in the form 10b5-1 Stock Option (Right to Buy) | −29,450 | 63,671 | D |
| 2026-01-07 | Exercise or conversion : show line 9 in the form 10b5-1 Stock Option (Right to Buy) | −31,261 | 32,410 | D |
Loading xslF345X05/ownership.xml…